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Background: The skin proteome contains valuable information on skin condition, but also on how skin may evolve
in time and may respond to treatments. Despite the potential of measuring regulatory-, effector- and structural
proteins in the skin for biomarker applications in clinical dermatology and skin care, convenient diagnostic tools are
lacking. The aim of the present study was to develop a highly versatile and non-invasive diagnostic tool for
multiplex measurements of protein biomarkers from the surface of skin.
Results: The Transdermal Analyses Patch (TAP) is a novel molecular diagnostic tool that has been developed to
capture biomarkers directly from skin, which are quantitatively analyzed in spot-ELISA assays. Optimisation of
protocols for TAP production and biomarker analyses makes TAP measurements highly specific and reproducible.
In measurements of interleukin-1α (IL-1α), IL-1 receptor antagonist (IL-1RA) and human β-defensin (hBD-1) from
healthy skin, TAP appears far more sensitive than skin lavage-based methods using ELISA. No side-effects were
observed using TAP on human skin.
Conclusion: TAP is a practical and valuable new skin diagnostic tool for measuring protein-based biomarkers from
skin, which is convenient to use for operators, with minimal burden for patients.
Keywords: Biomarker, Dermatology, Skin care, Diagnostics, Transdermal analyses patch, Interleukin 1α, Interleukin
1RA, CXCL-1, CXCL-2, β-defensin-1Background
The human skin is the largest organ of the integumentary
system, consisting of multiple layers of ectodermal tissue
that protects the underlying muscles, ligaments, bones and
internal organs of the body. Cells that reside in the skin,
such as keratinocytes, fibroblasts, melanocytes, Merkel cells
and Langerhans cells, or immune cells that migrate in and
out of the skin, are highly adaptive to the constantly
changing outer and inner milieus of the body to prevent e.
g. physical damage, temperature changes, dehydration and
pathogen invasion [1]. To ensure the integrity of skin, skin
cells secrete large amounts of structural, effector and
regulatory molecules, including scleroproteins (e.g. collagen* Correspondence: Pieter.Spee@fibrotx.com
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unless otherwise stated.type I and IV, keratin) [2-6], cytokines (e.g. IL-1α,
IL-1β, IL-1RA, TNF-α and IFN-γ) [7-12], chemokines
(e.g. CCL-1) [13,14], angiogenesis regulators (e.g. VEGF,
thrombospondin-1 and −2) [15-17] and anti-microbial pep-
tides (e.g. β-Defensin-1 (hBD-1) and −2 (hBD-2)) [17,18].
The integrity of skin is constantly threatened by external
factors (e.g. mechanical disruption, chemical influences,
extensive sun exposure, bacterial infections), but also from
‘within’ , for instance due to hormonal changes causing skin
ageing or the impact of chronic inflammation (e.g. psoriasis,
atopic dermatitis and systemic lupus erythematosus (SLE)).
Skin condition is often monitored visually. In dermatology,
for instance, clinical scores for psoriasis (Psoriasis Area
Severity Index score (PASI) score) and atopic dermatitis
(Scoring Atopic Dermatitis (SCORAD) score) are largely
based on visual assessments of clinical parameters, such as
skin redness, thickness, swelling, crustiness and scalingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tored by ultrasound, e.g. to determine the thickness and
density of skin layers (epidermis, sub-epidermal low-
echogenic band (SLEB) and dermis) [22,23]. Despite the
obvious value of these methods for monitoring skin condi-
tions at any given time, they have little predictive value for
how the condition of skin evolves over time, or whether
skin will respond to treatment.
Methods that may fulfill such needs are biomarker assess-
ments. Biomarkers are defined as a characteristic that is ob-
jectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmaco-
logical responses to therapeutic intervention [24]. Bio-
markers have been classified as: 1) Type 0 markers, which
correlate longitudinally with the natural history of the
disease, 2) Type I markers, which capture the effects of an
intervention in accordance with the mechanism of action
of the drug, and 3) Type II markers, which are surrogate
endpoints for changes that predict clinical benefits [25].
Biomarkers are of particular interest due to their predictive
value. For instance, presence of antibodies reactive with
cyclic-citrulinated peptide (CCP) in the blood is a fairly
accurate predictor of development of rheumatoid arthritis,
preceding clinical signs with months to even years. Several
studies have identified Type 0 biomarkers for pathological
skin conditions such as psoriasis and atopic dermatitis,
including biomarkers for keratinocyte activity (e.g. presence
of K16) and inflammatory response (e.g. up-regulation of IL-
8 and TNF-α) [26-32]. Type II biomarkers have been identi-
fied for various psoriasis and atopic dermatitis therapies,
including biomarkers representing Th17 pathway [33-35],
monocyte activity (e.g. TNF-α) [31], lymphocyte activity
(Granzyme B) and type I interferon pathways [16-24]. Of
particular interest is a study by Malaviya et al., showing that
the amount of cleaved Caspase-3-positive cells, accurately
predicts response to Enbrel, months before response to
therapy can be assessed based on clinical symptoms [25].
Biomarkers are usually biological molecules, such as
mRNA or proteins, or metabolites, derived from tissues or
body fluids (e.g. blood) via invasive methods. Recently,
Portugal-Cohen has published a non-invasive method in
which a limited number of soluble biomarkers could be
assessed in skin-lavage from lesional skin of a limited
number of psoriasis patients and renal failure [7,36,37]. A
clear increased concentration of IL-1α, TNF-α and IL-6
was found in skin lavage from lesion sites of psoriasis pa-
tients, in comparison with skin lavage from non-lesional
sites, or from skin of healthy individuals [7]. Similarly, tape
stripping of skin, in combination with proteomic analyses
of ‘captured’ proteins, has shown increased presence of in-
flammatory cytokines on inflamed or irritated skin [38-40].
Here we describe the step-by-step development of TAP.
The aim of this development was to generate a non-
invasive diagnostic tool for skin biomarker measurements,with a sensitivity and dynamic range, as well as conveni-
ence of use, which allows biomarker measurements from
different skin conditions. To minimize variation between
measurements, the core of TAP, consisting of an antibody
micro-array that allows multiplex analyses of selected bio-
markers, was optimized for optimal and reproducible cap-
turing of analytes from skin. Using IL-1α, IL-1RA, CXCL-1/
2 and hBD-1 as model biomarkers, protocols have been
developed for qualitative and quantitative analyses of bio-
markers from skin using spot-ELISA directly on TAP.
Results
Design of the transdermal analyses patch
For the selective capturing of soluble proteins directly
from skin, we have developed a so-called Transdermal
Analyses Patch (TAP), consisting of a micro-array, which
is supported by a dermal adhesive plaster for easy fixture
to skin (see Figure 1A). TAP micro-arrays contain a
panel of capturing antibodies, of which each antibody
variant is printed, in multitude, as discrete spots on
nitrocellulose by non-contact dispensing. In addition,
each TAP micro-array contains a multitude of spots each
printed with positive controls (IgG) or negative controls
(irrelevant IgG of printer buffer) to determine the speci-
ficity of biomarker measurements. In between the anti-
body micro-array and the plaster, a layer is positioned
that serves as a fluid reservoir for the buffer needed for
protein capturing from skin. In addition, this expandable
layer serves as a pressure pad to ensure close contact of
the micro-array to the skin (see Figure 1B). Captured
proteins are analyzed, both qualitatively and quantita-
tively, on the antibody micro-array using spot-ELISA.
Generation of capture antibody micro-arrays
Accurate TAP biomarker measurements require micro-
arrays that stably retain capturing antibodies during ana-
lyses and that display minimal variation between individual
spots of printed capture antibodies. Therefore, different
printing solutions were tested for the generation of stable
TAP micro-arrays with minimal variation between printed
spots. For this, nitrocellulose strips of Whatman Protran
BA 85 nitrocellulose (0.45 μm porosity) were printed with
five different amounts (1.2, 0.6, 0.3, 0.15 and 0.075 ng/spot)
of human IgG, in five fold, dissolved in PBS formulations
containing either 10% or 20% glycerol, that were supple-
mented or not with various concentrations of either etha-
nol, Triton-X100 or Tween-20 (see Figure 2 for details).
Printed IgG was visualised by spot-ELISA, using HRP-
conjugated secondary antibodies specific for the printed
IgG. Printed IgG was quantitatively analyzed by determin-
ing the pixel intensities of digitised images of the visualised
IgG and differences in spot intensities of the spots were
measured for each amount of IgG printed with the different
printing buffers tested. Regression analyses revealed very
view from top 




Figure 1 The Transdermal Analyses Patch (TAP). Panel A: TAP consists of a plaster with a nitrocellulose core that contains the capture
antibody micro-array, which is clearly visible in the middle. Panel B: In the lower photo, TAP has been fixed to skin. In the upper photo, it is clearly
visible that the layer in between the micro-array and the adhesive layer expands upon contact with fluid. This layer serves as a reservoir for the
buffer used for biomarker extraction from skin, as well as to ensure close contact between capture antibody micro-array and skin during extraction.
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printed proteins for all but one of printing buffers tested
(R2 ≥ 0.98 for all buffers tested) (see Figure 2). Also, only
minor variation between individual spots was observed for
all printing buffers tested. CV values did not exceed 10%
for any but two of the combinations of printing buffers and
IgG amounts tested (see Figure 2). Nonetheless, substantial
differences in signal strengths were observed between print-
ing buffers used and how well dispensed capture antibodies
were retained on the membrane during the assay. Micro-
arrays printed with IgG dissolved in PBS + 20% glycerol
without any further additives yielded the highest signal
strength observed for the different printing buffers and was
therefore chosen for further TAP micro-array development.
In a similar fashion, different nitrocellulose membranes
were tested, to identify the optimal printing material for the
TAP capture antibody micro-arrays. Quantitative analyses
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Figure 2 Effects of different printing buffers on the detection of hum
(1.2, 0.6, 0.3, 0.15 and 0.075 ng /spot) were printed on Whatman Protran BA
was visualised in spot-ELISA and signals quantified by determining the pixe
the analyses results of printed IgG in different printing buffer consisting of
X-100, 0.5% Tween-20, 1% ethanol or nothing, or printing buffer consisting
X-100, 0.5% Tween-20, 1% ethanol or nothing (see Panel A for details). Eac
strips (N = 25 per data point). X-axis: human IgG amount per spot. Y-axis: St
0–255 grey scale. Panel B: R2 and CV (Coefficient of variation) value presenProtran BA 85 nitrocellulose, with porosities of either 0.1,
0.2 or 0.45 μm, or Amersham Hybond C-Extra, with
0.45 μm porosity, revealed only minor differences in
amounts of printed IgG in different spots during analyses
(see Figure 3). Very strong correlations were observed be-
tween spot intensities and amounts of printed proteins for
all materials tested (R2 > 0.99). Nonetheless, micro-arrays
printed on Whatman Protran BA 85 nitrocellulose with
0.45 μm porosity yielded the lowest CV values (3.3-5.3%)
for the different IgG amounts tested, indicating the least
variability between individually printed spots, and therefore
this material was chosen for further TAP development.
Optimisation of the protein capture and detection
protocol using capture antibody micro-arrays
Multiplex TAP protein measurements from skin require
optimal analytic conditions to secure specific and sensitive
measurements as well as a dynamic range that allows20% Glycerol
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of PBS + 20% glycerol, supplemented with either 0.1% or 0.05% Triton
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material R2 value CV (%) range 
>0.99 5.6 – 8.4 
>0.99 4.8 – 9.3 
>0.99 3.3 – 5.3 
>0.99 3.4 – 6.5 
Figure 3 Effects of different nitrocellulose materials on the detection of printed human IgG. Panel A: Various amounts of human IgG
(1.2, 0.6, 0.3, 0.15 and 0.075 ng /spot) were printed on Whatman Protran BA-85 (0.1, 0.2 or 0.45 μm porosity) or Amersham Hybond-C (0.45 μm
porosity) membrane using PBS + 20% glycerol as printing buffer. Printed IgG was visualised in spot-ELISA and signals quantified by determining
the pixel intensities of digitized spots. Each line on graph represents the analyses results of IgG printed on a specific nitrocellulose (see Panel A for details).
Each data point consists of measurements of five spots on five different strips (N = 25 per data point). X-axis: human IgG amount per spot. Y-axis: Staining
intensity defined as the mean pixel intensity measured on a 0–255 grey scale. Panel B: R2 and CV% (Coefficient of variation) range for each tested
nitrocellulose membrane type.
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1α, IL-1RA, the combination of CXCL-1 and −2 (referred
to as CXCL-1/2) and hBD-1 were chosen as model skin
analytes based on literature reports describing that these
proteins are expressed in healthy skin, and/or that these
proteins have altered expression patterns in lesional (e.g.
due to inflammation) or damaged (e.g. due to UV expos-
ure) skin [7,10-12,18,22,23,40-43]. For TAP micro-array
development, Whatman Protran BA 85 nitrocellulose
(0.45 μm porosity) strips were printed with three different
amounts of capturing IL-1α, IL-1RA, CXCL-1/2 or hBD-1
antibodies (see Methods for details). Strips were subse-
quently incubated with different concentrations of recom-
binant IL-1α, IL-1RA, CXCL-2 or hBD-1. Following
washing, strips were incubated with two different concen-
trations of anti-IL-1α, IL-1RA, CXCL-1/2 and hBD-1
detection antibodies and bound IL-1α, IL-1RA, CXCL-1/2
and hBD-1 were subsequently visualised using two differ-
ent concentrations of amplification solution and quantita-
tively analyzed as described. As shown in Figure 4,
exemplified by the data obtained for IL-1RA, the major
variable that influenced the sensitivity as well as the
dynamic range of recombinant IL-1RA measurements
was the amount of capture antibody printed on the nitro-
cellulose strips. The highest amount of anti-IL-1RA used,
2.25 ng per printed spot, yielded the highest sensitivity,
signal strength and dynamic range. The highest amount
of anti-IL-1RA capture antibodies used, in combination
with 10-fold diluted amplification reagents yielded the
highest curve fit (R2 > 0.99). For the detection of IL-1RA
from skin, 2.25 ng capture anti-IL-1RA per spot waschosen for printing TAP micro-arrays, in combination
with a spot-ELISA protocol using 166.67 ng/ml detec-
tion anti-IL-1RA and a 1/10 fold dilution of amplifica-
tion reagent. Optimal use of reagents for detection of
IL-1α, CXCL-1/2 and hBD-1 were determined in a simi-
lar fashion.
To test TAP protein measurements from skin, micro-
arrays with anti-IL-1α, −IL-1RA, −CXCL-1/2 and -hBD-1
capturing antibodies were produced that were extensively
tested for cross-reactivity of reagents. No cross-reactivities
of reagents were observed (data not shown), indicating
that TAP measurements of IL-1α, IL-1RA, CXCL-1/2 and
hBD-1 from skin should be considered specific.
Protein measurements from skin using TAP
TAP containing anti-IL-1α, −IL-1RA, −CXCL-1/2 and
-hBD-1 capturing antibody micro-arrays were applied to
normal, non-sun exposed skin on the inside of the lower
arm of healthy volunteers (N = 3) for 1, 5, 15 or 30 minutes.
Captured IL-1α, IL-1RA, CXCL-1/2 and hBD-1 were sub-
sequently visualised using anti-IL-1α, −IL-1RA, −CXCL-1/2
and -hBD-1 detection antibodies in spot-ELISA, and quan-
titatively analyzed, as described. As shown in Figure 5, IL-
1α, IL-1RA and hBD-1 could be efficiently detected on
normal skin using TAP, whereas CXCL-1/2 was not
detectable. Maximal signal strength was obtained follow-
ing 15 minutes incubation on skin, however, no statisti-
cally significant differences were observed between 5, 15
and 30 minutes. An incubation time of 20–30 minutes
was used in following experiments, to minimize variability in
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Figure 4 Measurements of recombinant IL-1RA. Measurements of recombinant IL-1RA, using 0.75 (triangles), 1.5 (squares) and 2.25 (diamonds)
nanogram of anti-IL-1RA capturing antibody printed on nitrocellulose membranes, and a combination of either 500 or 166.67 ng/ml anti-IL-1RA
detection antibody and 10% or 20% amplification reagents in spot-ELISA. Each data point consists of 10 measurements (N = 10). Each line
presents an average mean of measurements obtained from duplicate. X-axis: Recombinant IL-1RA in ng/ml. Y-axis: Staining intensity defined as
the mean pixel intensity measured on a 0–255 grey scale.
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To measure the reproducibility of TAP biomarker mea-
surements from skin, TAP biomarker measurements were
performed on three different skin areas from healthy vol-
unteers (N = 10) on five consecutive days. For this, FibroTx
TAP containing anti-IL-1α and -IL-1RA capturing anti-
body micro-arrays were incubated on normal appearing
skin on cheek (face), collar bone (neck) and on the inside
of the lower arm (lower forearm) of healthy volunteers for
20 minutes. FibroTx TAP capture antibody micro-arrays
were collected after incubation on skin and stored at 4°C
until further analysis. This procedure was repeated the four
following days, at the same positions on the different skin
areas, approximately at the same time of day. Captured IL-
1α and IL-1RA were visualised using anti-IL-1α and -IL-
1RA detection antibodies in spot-ELISA, and quantitatively
analyzed, as described. As shown in Figure 6, IL-1α and
IL-1RA could be efficiently detected on all three different
skin areas using TAP. Notably, whereas IL-1α is found in
the neck region and on the inside of the lower arm in
higher amounts than IL-1RA, the reverse pattern isobserved on facial skin (see Figure 6A). There was little
day-to-day variation in amounts of IL-1α and IL-1RA on
five consecutive days, with average CV values of 21.1% and
18.4%, respectively (see Figure 6B).
Benchmarking of TAP protein measurements from skin
with protein measurements from skin lavage
To benchmark the efficacy of TAP protein measurements
from skin, TAP protein measurements were performed in
parallel using skin lavage. For this, TAP containing micro-
arrays with anti-IL-1α, −IL-1RA, −CXCL-1/2 and -hBD-1
capturing antibodies were applied in two-fold to normal
skin on the lower arm of healthy volunteers (N = 10). Cap-
tured IL-1α, IL-1RA, CXCL-1/2 and hBD-1 were subse-
quently visualised using anti-IL-1α, −IL-1RA, −CXCL-1/2
and -hBD-1 detection antibodies, in spot-ELISA, as de-
scribed. Three different formats of protein detection using
skin lavage were applied. In the first method, skin lavage
was performed essentially as previously described by
Portugal-Cohen [7,36,37]. In short, silicone rings were fixed
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Figure 5 Measurements of IL-1α, IL-1RA, CXCL-1/2 and hBD-1 from healthy skin. TAP’s containing capture antibody micro-arrays coated
with anti-IL-1α, −IL-1RA, −CXCL-1/2 and -hBD-1 capture antibodies were incubated on skin for 1, 5, 15 or 30 minutes. IL-1α, IL-1RA, CXCL-1/2 and
hBD-1 captured from skin were analyzed in spot-ELISA and signals were quantified by determining the pixel intensities of digitized spots. Signal
intensities were compared to signals obtained using fixed concentrations of recombinant IL-1α, IL-1RA, CXCL-1/2 and hBD-1 captured in solution.
In the graph, the apparent average concentration of IL-1α (Panel A), IL-1RA (Panel B) CXCL-1/2 (Panel C) and hBD-1 (Panel D) on skin of three
persons has been plotted against incubation time on skin. Each data point in the graphs represents results of three spots analyzed on 6 TAP’s
(N = 18). Y-axis: Apparent concentration of IL-1α, IL-1RA, CXCL-1/2 or hBD-1 on skin in ng/ml. X-axis: Incubation time on skin in minutes. Error bars
on graph present standard deviation of analyzed data points (N = 18).
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CXCL-1/2 and hBD-1 in skin lavage was qualitatively and
quantitatively analyzed using sandwich ELISA. In the second
method, skin lavage was applied to TAP micro-arrays
in vitro, and captured IL-1α, IL-1RA, CXCL-1/2 and hBD-1
were subsequently analyzed similar to the method used for
quantitative analyses of proteins captured directly from skin
using TAP. In the third method, TAP micro-arrays were
incubated in skin lavage on the patient in situ and captured
IL-1α, IL-1RA, CXCL-1/2 and hBD-1 was subsequently ana-
lyzed similar to the method used for quantitative analyses of
proteins captured directly from skin using TAP. All four
methods were capable of detecting IL-1α, IL-1RA and hBD-
1 from skin, with the exception of the ELISA method used
for hBD-1 (see Figure 7, panels A, B and D). In contrast,
none of the methods were capable of detecting CXCL-1/2
(see Figure 7, panel C). Clear differences were observed in
the efficacy of protein measurements from the skin. TAP
was by far the most sensitive method used, yielding apparent
concentration values 20- (IL-1α) and 15- (IL-1RA) fold in
excess of the values found using a combination of skin
lavage and ELISA. Using TAP capture antibody micro-arraysfor the analyses of IL-1α, IL-1RA, CXCL-1/2 and hBD-1
from skin lavage yielded only marginal improvements in
detection efficacy over ELISA. Since TAP uses the same
micro-arrays, this suggests that the greater efficacy of TAP
may be related, at least in part, to differences in the concen-
tration of skin proteins in skin lavage and in the fluid on the
interface between micro-array and skin in the TAP proced-
ure. Then again, applying the capture antibody micro-arrays
in skin lavage in situ proved approximately 8- (IL-1α) and
3.5- (IL-1RA) times more efficient than applying the same
skin lavage to capture antibody micro-arrays in vitro,
suggesting that capturing proteins directly from skin, as
performed during the TAP procedure and during the
capturing proteins using micro-arrays in situ, is far
more efficient than capturing of skin proteins from skin
lavage in vitro.
Discussion
Skin biomarker measurements have enormous value for
detailed assessment of skin conditions, both for clinical
applications and in skin care. Biomarkers secreted on
skin can be used to assess the condition of skin at a
Figure 6 Measurements of IL-1 α and IL-1RA from three different skin regions on healthy volunteers on five consecutive days.
TAP’s containing capture antibody micro-arrays coated with anti-IL-1α and -IL-1RA capture antibodies were incubated on skin of the inner side of
the lower arm (‘Forearm’), cheek (‘Face’) or collar bone (‘Neck’) regions of ten healthy volunteers for 20 minutes. The capturing procedure was
repeated on the four following days on exact the same regions, at around the same time-point of day. IL-1α and IL-1RA captured from skin were
analyzed in spot-ELISA and signals were quantified by determining the pixel intensities of digitized spots. Signal intensities were compared to
signals obtained using fixed concentrations of recombinant IL-1α and IL-1RA, captured in solution. In graph A, the apparent average concentrations of
IL-1α black bars and IL-1RA (white bars) have been plotted for the three different body regions. In graph B, the apparent average concentrations of
IL-1α black bars and IL-1RA (white bars) have been plotted for the three different body regions for each of the ten persons (1–10 in graphs) analysed.
Y-axis: Apparent concentration of IL-1α and IL-1RA on skin in ng/ml. X-axis: Individual participants labeled 1–10. Error bars in graph A represent the
standard deviations from average of combined measurements in the 10 healthy volunteers. Error bars in graph B, represent the standard deviations
from the average of measurements from five different days for each of the healthy volunteers.
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given skin condition may progress in time, or how skin
may react to treatments. Skin biomarker measurements
are usually performed via invasive methods that are un-
pleasant for patients and that require specialised laborator-
ies for analyses. In recent years, methods have been
developed for the analyses of skin biomarkers by non-
invasive methods, based on the extraction of biomarkers
from the surface of skin. Using skin-lavage to extract bio-
markers from the surface of skin, Portugal-Cohen et al.
have shown clear differences in expression levels of skin
hydrophilic biomarkers, including cytokines (IL-1α, TNF-α
and IL-6) and antioxidants (uric acid, total antioxidant
scavenging capacity), between lesional and non-lesional
skin in patients with atopic dermatitis and psoriasis [7,36].
Similarly, Portugal-Cohen et al. found significant elevations
in the expression of IL-10, TNF-α and uric acid on skin of
hemodialysis patients with chronic renal failure, in com-
parison with healthy individuals, suggesting that skin bio-
marker analyses may be useful for monitoring patients with
a variety of diseases with dysfunctional skin manifestations,
as well [37]. Another method involves analyses of analytes
from dead skin cells obtained from skin by tape stripping
methods, e.g. using D-Squame tape. Using tape-stripping in
combination with mass spectrometry analyses, Emson et al.
have recently shown that they could detect marked quanti-
tative differences in keratinocyte turn-over between lesional
and non-lesional skin on psoriasis vulgaris patients [44].TAP was designed with two goals in mind. The first
goal was to develop a highly versatile and sensitive tool
for accurate multi-analyte biomarker measurements
from the surface of skin. The second goal was to ensure
that TAP was easy to use with a minimal burden for
patients. To achieve the first goal, the core of TAP was
designed as a capture antibody micro-array. The capture
antibody micro-arrays allow multi-analyte capturing of
biomarkers directly from skin, using minimal amount of
fluid between TAP and skin, ensuring much higher con-
centrations of biomarkers during biomarker capturing
than skin lavage-based methods, or during the analyses
of individual biomarkers from tape-stripping. In our
benchmark studies we found that TAP was far more
sensitive than antibody based methods using skin lavage
techniques in our assays, which in part could be attrib-
uted to differences in the amount of fluid used for the
biomarker capturing process. However, we also observed
that applying capture antibody micro-arrays in situ, i.e.
during skin lavage on skin, was more sensitive than cap-
turing biomarkers from the same skin lavage in vitro.
This indicates that capturing of biomarkers directly from
skin surface may have other advantages, as well. At
present time it is unclear what causes this effect, although
one may speculate that analytes captured directly from
skin may somehow be protected from degradation by
capturing antibodies, which is not the case when analytes



















































Figure 7 Measurements of IL-1α, IL-1RA, CXCL-1/2 and hBD-1 from healthy skin using TAP and from skin lavage techniques. TAP
measurements of IL-1α, IL-1RA, CXCL-1/2 and hBD-1 from healthy skin were analyzed and compared with three different methods using skin
lavage. See text for details. Signal intensities for the different methods were compared to signals obtained using fixed concentrations of recombinant
IL-1α, IL-1RA, CXCL-1/2 and hBD-1 captured in solution. In the graphs, it is clearly visible that TAP is the most sensitive method for the detection of
IL-1α (panel A), IL-1RA (panel B) and hBD-1 (panel D) on skin. CXCL-1/2 (panel C) could not be detected by any of the methods. Each data point in the
graphs represents the results of two spots analyzed on 20 TAP’s (N = 10). Y-axis: Apparent concentration of IL-1α, IL-1RA, CXCL-1/2 or hBD-1 on skin in
ng/ml. X-axis: Incubation time on skin in minutes. Error bars on graph present standard deviation of analyzed data points (N = 10).
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the printing process of the capture micro-arrays. Printing
buffers can highly impact the printing of proteins on nitro-
cellulose, as well as the specifications of nitrocellulose itself
[45,46]. We found that PBS supplemented with 20% gly-
cerol yielded the highest sensitivity. Since the same
amounts of IgG were used for optimisation of printing, we
conclude that the benefit of PBS + 20% glycerol is that it
yields the most stable interaction between IgG and nitrocel-
lulose during the biomarker binding process. Although we
did not find any remarkable differences between different
nitrocellulose materials used, from different suppliers, and
with different porosities, we observed that Whatmann
Protran BA85 (0.45 μm porosity) yielded the least variability
between printed spots, and hence this material was chosen
for TAP production.
In our assays to find the optimal conditions for skin bio-
marker measurements, using IL-1α, IL-1RA, CXCL-1/2
and hBD-1 as model analytes, we found that the amountof capture antibody printed on the capture antibody
micro-array was the most important factor that deter-
mined both sensitivity and dynamic range of measuring
analytes in vitro. The higher the amount of capture anti-
bodies used, the highest the signal strength, sensitivity and
dynamic range of measurements achieved in our experi-
ments. The combination of amount of detection antibody
used in our biomarker analyses, and concentration of ampli-
fication reagents used, impacted predominantly the curve fit
of the concentration range, and thus the accuracy of mea-
surements that can be achieved. Optimal settings, which
changed somewhat between analytes measured, yielded R2
values of over 0.99, thus indicating that highly accurate bio-
marker measurements with TAP can be achieved.
To achieve the second goal, convenience of use, we de-
signed TAP as an adhesive bandage. The bandage allows
easy fixture of the TAP capture antibody micro-array to
skin. This, and the fact that TAP uses a sponge layer as an
expandable fluid reservoir that ensures close contact
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to gravity issues e.g. such as observed using skin-lavage
techniques. In addition, the relatively small size of the
TAP micro-array allows measurements of small skin le-
sions, e.g. as observed in certain forms of psoriasis or bac-
terial infections, e.g. from tick bites. The methods used for
TAP biomarker analyses have been based in large on well-
established techniques. In essence, TAP biomarker ana-
lyses are based on sandwich ELISA, which is a standard
and cost-effective technique for qualitative and quantita-
tive protein analyses established in laboratories all over
the world. The design of the micro-array allows for easy
adaptation to different sets of capture and detection anti-
bodies used, and thus specific TAP’s for specific purposes
can be designed with relative ease. Using TAP, we could
detect IL-1α, IL-1RA and hBD-1 from normal skin of
healthy volunteers, but not CXCL-1/2 due to its low
expression on normal skin. Measuring IL-1α and IL-1RA
on the skin of healthy volunteers on five consecutive days,
we could show that TAP biomarker levels fluctuated with
a CV of around 20%. Since the CV values of TAP mea-
surements under ideal conditions are around 5%, we con-
clude that there is a low day-to-day variation in biomarker
presence on skin. From these measurements it became ap-
parent that the ratio between IL-1a and IL-1RA is differ-
ent on skin in the lower inner arm and neck regions, in
comparison with facial skin, which is very much in align-
ment with tape-stripping studies performed by Hirao et al.
showing that IL-RA is much higher expressed the stratum
corneum of sun-exposed skin areas (e.g. the face) than in
areas (e.g. inner forearm) not exposed to sun-light [47].
These biomarkers were chosen because they have been
described as regulated proteins in different skin condi-
tions, such as atopic dermatitis and psoriasis. Currently,
studies are ongoing with TAP to study the expression of
various biomarkers in different skin conditions, including
psoriasis, and we can see clear differences between skin
affected and skin not affected by disease (manuscript in
preparation). Using TAP on skin, no adverse effects, such
as redness or itching were observed, and thus we can con-
clude that TAP is a highly convenient and versatile new
diagnostic tool for non-invasive biomarker measurements
from skin that is safe to use.
Conclusions
With TAP, we could capture and measure a selection of
regulatory proteins expressed in the skin, IL-1α, IL-1RA
and hBD-1, from the surface of normal skin of healthy
volunteers, thus presenting TAP as a practical and highly
sensitive skin-diagnostic tool for measuring protein-
based biomarkers from skin with minimal effort for
operators, as well as with minimal burden for persons
being analyzed. No adverse effects, such as redness or
itching were observed, and thus we conclude that TAPis a highly convenient and versatile new diagnostic tool
for non-invasive biomarker measurements from skin
that is safe to use.
Methods
Antibodies
Human GRO-ß (CXCL-2) ELISA Development Kit (Cat.
No: 900-K120, PeproTech), Human IL-1α ELISA Devel-
opment Kit (Cat. No: 900-K11, PeproTech), Human
hBD-1 ELISA Development Kit (Cat. No: 900-K202,
PeproTech), Human IL-1RA ELISA Development Kit
(Cat. No: 900-K474, PeproTech), Human IgG (Lab AS,
Estonia), Goat anti-human IgG Lab AS, Estonia).
Human IgG printing on nitrocellulose
Human IgG was diluted in PBS (pH = 7.4) with 10% or
20% (v/v) glycerol (Scharlau Chemie), supplemented with
either 0.1% or 0.05% Triton X-100 (Scharlau Chemie),
0.5% Tween-20 (AppliChem), 1% ethanol or no supple-
ment to concentrations of 2.5, 5, 10, 20 and 40 μg/ml.
Droplets (30 nl) containing 0.075, 0.15, 0.3, 0.6 and 1.2 ng
per spot of human IgG were deposited on Whatman
Protran BA 85 nitrocellulose membrane strips, with po-
rosities of either 0.1, 0.2 or 0.45 μm, or Amersham
Hybond C-Extra, with 0.45 μm porosity, using a non-
contact dispenser printer (AD3400, BioDot). Each protein
amount was printed in 5 replicates. To avoid any unspe-
cific protein binding, nitrocellulose strips were blocked
with blocking buffer (PBS + 5% (w/v) BSA (PAA Labora-
tories GmhH) for one hour at room temperature. Strips
were dried at room temperature after washing in PBS and
milli-Q water and stored at 4°C.
For FibroTx TAP development pre-washed and dried
nitrocellulose strips of Whatman Protran BA 85 (0.45 μm
porosity) containing 0.75, 1.5 and 2.25 ng /spot anti-IL-
1α, −IL-1RA, −hBD-1 and -CXCL-2 antibodies dissolved
in PBS (pH = 7.4) and 20% (v/v) glycerol were generated
essentially as described.
Visualisation of printed human IgG spots using spot-
ELISA
Nitrocellulose strips with printed human IgG spots were
incubated with 1 μg/ml HRP-conjugated goat anti-human
IgG in PBS + 0.05% (v/v) Tween-20 + 1% (w/v) BSA for
45 minutes at room temperature. After washing with PBS
+ 1% (w/v) BSA + 0.1% (v/v) Tween-20, human IgG spots
were visualised using 20% Substrate-Chromogen solution
diluted in Substrate Buffer Concentrate (Dako, K-1500).
The reaction was stopped with milli-Q water.
Visualisation of captured proteins using spot-ELISA
For the standard curves, recombinant IL-1α, IL-1RA,
hBD-1 and CXCL-2 were diluted in PBS, 0.05% (v/v)
Tween-20, 1% (w/v) BSA and incubated for 30 min at
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washed from membrane with wash buffer containing
PBS, 1% (w/v) BSA, 0.1% (v/v) Tween-20. Biotinylated
secondary antibody were added to membrane strips in
two concentrations and incubated for 45 min at room
temperature. For signal amplification Catalysed Signal
Amplification (CSA) System (Dako, K-1500) was used.
Streptavidin-Biotin Complex, Amplification Reagent
and Streptavidin-HRP were diluted in PBS, 0.05% (v/v)
Tween-20 up to 10% or 20%. For signal visualisation
Substrate-Chromogen solution diluted in Substrate
Buffer Concentrate was used. The reaction was stopped
with milli-Q water.
Biomarker measurements from skin
Ethical approval for the studies was covered by the
Tallinn Medical Research Ethical Committee (Decision
No. 2551). No visual signs of a reaction on skin towards
the FibroTx TAP capture antibody micro-array system,
such as itching, redness or any other discomfort was
observed.
Skin lavage
A four-ring silicon device (Greiner Bio-One) was placed on
the inside of the lower arm of healthy volunteers (N = 10)
and fixed with a tubular net bandage (Kaigert). All rings
were filled with 900 μl PBS (pH = 7.4) and incubated on
skin for 30 minutes. For the capturing of biomarkers dir-
ectly from skin, TAP capture antibody micro-arrays were
placed into two rings during skin lavage. After incubation,
lavage solution where no TAPs were present was collected
into sterile 15 ml tubes (Greiner Bio-One). Micro-arrays
incubated in skin lavage were collected into 1.5 ml tubes
(Eppendorf) and stored at 4°C until further analysis.
Enzyme-linked immunosorbent assay (ELISA)
The levels of hBD-1, CXCL-1/2, IL-1α and IL-1RA secreted
into skin surface were measured using human hBD-1, Gro-
β (which identifies both CXCL-1 (Gro-α) and −2 (Gro-β) in
our assays), IL-1α and IL-1RA ELISA Development Kits. In
short, skin lavage liquid was centrifuged at 13. 000 rpm for
5 minutes and 50 μl /well of fluid was analyzed in high bind-
ing ELISA plates (Greiner BioOne), at room temperature,
according to the manufacturer's instructions. Signal optical
density was measured using a Spectramax 340 PC photo-
spectrometer (Molecular Devices) 450 nm.
TAP biomarker measurements on skin
Biomarker measurements from skin were performed using
TAP capture antibody micro-arrays. Each micro-array,
printed on nitrocellulose membrane, contained two spots
of biomarker capturing antibody: 0.75 ng and 1.5 ng of
IL-1α, 2.25 ng hBD-1, 2.25 ng CXCL-2, 2.25 ng IL-1RA
per spot, additionally, each micro-array contained anegative control (PBS-with 20% (v/v) glycerol) and posi-
tive control (0.03 ng biotinylated anti- hBD-1).
In order to assess the amounts of IL-1α, IL-1RA,
CXCL-1/2 and hBD-1 on skin, TAP capture antibody
micro-arrays coated with anti-IL-1α, anti-IL-1RA, anti-
CXCL-1/2 and anti-hBD-1 were applied in duplicates to
the inside of the lower arm of healthy volunteers (N = 10),
both men and women. FibroTx TAP capture antibody micro-
arrays were wetted on skin with 150 μl PBS (pH=7.4) and
incubated for 30 minutes. Following incubation, TAP capture
antibody micro-arrays were collected from the skin and
stored at 4°C until further analysis. Captured IL-1α, IL-1RA,
CXCL-1/2 and hBD-1 were visualised using spot-ELISA.
Spot-ELISA
48-well plates (Greiner BioOne) were blocked with 1%
BSA (w/v) in PBS (pH = 7.4). Subsequently, wells were
washed with milli-Q water and dried. For further pro-
cessing TAP capture antibody micro-arrays were placed
into blocked 48-well plates and wetted with PBS.
To create standard curves, capture antibody micro-
arrays were incubated for 30 minutes at 33°C with a mix-
ture of hBD-1, CXCL-2, IL-1α and IL-1RA recombinant
proteins diluted in PBS + 0.05% (v/v) Tween-20 + 1% (w/v)
BSA. For analyses of biomarkers from skin lavage, TAP
micro-arrays were incubated with 150 μl/well of lavage so-
lution for 30 min at 33°C. The capture antibody micro-
arrays were washed subsequently with PBS + 0.1% (v/v)
Tween-20 + 1% (w/v) BSA before further processing, simi-
lar to FibroTx TAP capture antibody micro-arrays col-
lected from skin and from lavage solution.
Subsequently the micro-arrays were washed with wash
buffer and incubated with specific biotinylated detection
antibodies mix containing anti-hBD-1 (333.33 ng/ml),
anti-CXCL-1/2 (166.67 ng/ml), anti-IL-1α (142.86 ng/
ml) and anti-IL-1RA (166.67 ng/ml), for 45 min at room
temperature. For micro-array signal enhancement, 10%
CSA System components were used as described. Signal
was visualised using 20% Substrate-Chromogen solution
diluted in Substrate Buffer Concentrate. Reaction was
stopped with milli-Q water.
Signals of captured IL-1α, IL-1RA, CXCL-1/2 and hBD-1
were quantified by comparing the signals of these proteins
captured from skin of healthy volunteers using FibroTx
TAP capture antibody micro-array and lavage method with
signals from FibroTx TAP capture antibodies micro-arrays
incubated with fixed amounts of recombinant IL-1α, IL-
1RA, CXCL-1/2 and hBD-1.
TAP biomarker measurements on skin for biomarker
variation determination in time
Biomarker measurements from skin were performed using
TAP capture antibody micro-arrays containing three spots
of biomarker capturing antibody: 0.3 ng of IL-1α and
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contained a negative control (PBS-with 20% (v/v) glycerol)
and positive control (0.03 ng biotinylated anti- hBD-1).
TAP capture antibody micro-arrays coated with anti-IL-1α,
anti-IL-1RA were applied in duplicates to the face area, col-
lar bone and inside of the lower arm of healthy volunteers
(N = 10), including both men and women. FibroTx TAP
capture antibody micro-arrays were incubated on skin for
20 minutes. Following incubation, TAP capture antibody
micro-arrays were collected from the skin and stored at 4°C
until further analysis. Captured IL-1α and IL-1RA, were
visualised using spot-ELISA. Signals of captured IL-1α and
IL-1RA were quantified by comparing the signals of these
proteins captured from skin of healthy volunteers using
FibroTx TAP capture antibody micro-array with signals from
FibroTx TAP capture antibodies micro-arrays incubated with
fixed amounts of recombinant IL-1α and IL-1RA.
Image analyses
Processed TAP capture antibody micro-arrays and nitro-
cellulose strips were scanned with a flat-bad scanner
(Canon) at 1200 dpi resolution, using a 0–255 grey-scale,
and analyzed with Adobe Photoshop Elements software.
Processed TAP capture antibody micro-arrays for bio-
marker variation determination in time were scanned with
FibroTx TAP scanner, using a RGB scale. On both cases
biomarker signals were corrected for background staining.
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